

Replicate Bioscience Announces Collaborative Agreement with Instituto Butantan

Client News December 4, 2025

Gunderson Dettmer represented client Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology, in a collaboration agreement with Instituto Butantan, a leading nonprofit producer of immunobiologic products in Brazil.

Replicate Bioscience is amplifying the power of RNA therapeutics to overcome the shortcomings of existing mRNA approaches, with potential improvements in bioactivity, induction of more potent immune responses, and improved therapeutic index.

Under the agreement, Instituto Butantan will obtain exclusive rights to develop and commercialize Replicate's novel srRNA rabies vaccine RBI-4000 in Brazil and other Latin American countries. The collaboration will also accelerate improvement of cold chain storage and thermostability, which may bolster adoption of srRNA technology and support a cost advantage versus conventional vaccine technologies.

In the announcement of the agreement, Replicate Bioscience CEO Nathaniel Wang, Ph.D said, "We are honored to collaborate with Instituto Butantan, a global leader in the fight against deadly infectious diseases. We view this as an exciting opportunity to clinically advance Replicate's srRNA rabies vaccine with Butantan and expand our scientific, operational, and manufacturing frameworks that can be applied to other diseases."

The Gunderson deal team was led by Brendan McCarthy and included Anthony Farnesi.

Companies Replicate Bioscience Instituto Butantan

Related People



Brendan C. McCarthy
PARTNER
P +1 858 436 8013



Anthony Farnesi ASSOCIATE P +1 858 436 8074

Related Services

Life Sciences
Private & Public Companies

Featured Insights

EVENTS

Webinar: Paradigm Shift? Mandatory Securities Arbitration and the Impact of the SEC's Recent Policy Statement for Companies and Investors

FIRM NEWS

Amidst Strong Year, Gunderson Dettmer Elects Nine New Partners

EVENTS

Webinar: AI in the Workplace: Legal Challenges and Best Practices

FIRM NEWS

2025 CVCA Annual General Meeting & Private/Venture Capital Summit in Beijing

CLIENT NEWS

Gunderson Dettmer Represented Hims & Hers in Acquisition of Livewell

CLIENT NEWS

Gunderson Client Neptune to Be Acquired by OpenAl

CLIENT NEWS

Hims & Hers Announces Definitive Agreement to Acquire YourBio Health

CLIENT NEWS

LotusFlare Announces Equity Investment from Ericsson

PUBLIC VENTURES

SEC Chair Charts Disclosure Overhaul to Revive IPOs: Materiality and Scale Over 'Regulatory Creep'

CLIENT NEWS

Vambe Raises \$14M Series A Led by Monashees

CLIENT NEWS

Gunderson Dettmer Represented Veza in Acquisition by ServiceNow

CLIENT NEWS

Cenit Announces \$1.8M Seed Financing